Within the cord blood industry, there was a strong growth period during the 2000’s. However, over the past few years, the market has substantially matured and consolidated. While strong industry growth continues within North Asia (particularly China, Hong Kong, and Taiwan) and Southeast Asia (led by India and Malaysia), growth of the North American market is flat and the European cord blood banking market is declining. [Read more…]
Edinburgh, UK. 10 May 2016 — The merger was announced today of Roslin Cell Sciences and Roslin Cellab, two companies previously created as spin outs from the Roslin Institute and both focused on using stem cells to discover new drugs. Following the merger, the parent company has been renamed Censo Biotechnologies Ltd with Roslin Cell Sciences Ltd continuing to trade as a wholly owned subsidiary.
Censo Biotechnologies has extensive capacity to create and use induced Pluripotent Stem Cells (iPSCs) for drug discovery research with sites in Edinburgh and Cambridge, UK. The Company uses this capacity to produce stem cells from large diverse groups of individuals, so that drug development companies can understand how the efficacy of their drugs varies across the population. This underpins faster drug development and enables the right drug to be targeted to the right patient. [Read more…]
Pfizer PLC Nudges Out Novartis AG to Become the New Behemoth in the Drug World
In breaking news released today, Pfizer and Allergan announced that they are executing a reverse merger worth $160 billion. Yes, billion with a “B.” This is a massive deal and will position the newly combined company as the largest pharmaceutical company in the world, bumping out current leader, Switzerland’s Novartis AG, for 1st place.
To secure a lower tax rate, Allergan is technically buying Pfizer, although the numbers do not indicate that to be true. Allergan stock holders will get 11.3 shares of the combined company for each of their shares, while Pfizer stockholders will only get a one-to-one exchange for their shares (one existing share of Pfizer stock for one new shared of the combined company).
In a classic move to allow brand continuity for the more dominant brand name, Pfizer and Allergan will be renamed as “Pfizer PLC.” [Read more…]